HBM Holdings 향후 성장

Future 기준 점검 0/6

HBM Holdings 의 수익과 수익은 각각 연간 7.2% 및 25.5% 감소할 것으로 예상됩니다. EPS는 연간 29% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 11% 로 예상됩니다.

핵심 정보

-25.5%

이익 성장률

-28.98%

EPS 성장률

Biotechs 이익 성장	45.4%
매출 성장률	-7.2%
향후 자기자본이익률	11.03%
애널리스트 커버리지	Low
마지막 업데이트	22 Aug 2025

최근 향후 성장 업데이트

Recent updates

Subdued Growth No Barrier To HBM Holdings Limited (HKG:2142) With Shares Advancing 54%

Aug 16

What HBM Holdings Limited's (HKG:2142) 51% Share Price Gain Is Not Telling You

May 07

HBM Holdings' (HKG:2142) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 29

HBM Holdings Limited (HKG:2142) Stock Catapults 78% Though Its Price And Business Still Lag The Industry

Feb 20

HBM Holdings Limited (HKG:2142) Stock Catapults 58% Though Its Price And Business Still Lag The Industry

Jan 01

Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump

Oct 02

Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet

Jul 18

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

May 23

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Apr 12

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jan 01

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

Feb 08

이익 및 매출 성장 예측

SEHK:2142 - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	116	60	24	N/A	2
12/31/2026	91	24	31	23	3
12/31/2025	169	73	53	35	2
6/30/2025	116	73	50	50	N/A
3/31/2025	77	38	40	40	N/A
12/31/2024	38	3	30	31	N/A
9/30/2024	55	12	25	26	N/A
6/30/2024	72	21	20	21	N/A
3/31/2024	81	22	-1	1	N/A
12/31/2023	90	23	-22	-19	N/A
9/30/2023	72	-19	-43	-38	N/A
6/30/2023	54	-61	-64	-56	N/A
3/31/2023	47	-99	-91	-78	N/A
12/31/2022	41	-137	-118	-100	N/A
9/30/2022	35	-143	-120	-98	N/A
6/30/2022	30	-149	-122	-97	N/A
3/31/2022	17	-144	-131	-111	N/A
12/31/2021	4	-138	-140	-126	N/A
9/30/2021	7	-224	-114	-106	N/A
6/30/2021	10	-310	-88	-87	N/A
3/31/2021	12	-303	-62	-61	N/A
12/31/2020	14	-296	-36	-35	N/A
9/30/2020	13	-187	-41	-38	N/A
6/30/2020	11	-78	-45	-42	N/A
3/31/2020	8	-73	-52	-44	N/A
12/31/2019	5	-67	-59	-46	N/A
12/31/2018	1	-35	N/A	-33	N/A

애널리스트 향후 성장 전망

수입 대 저축률: 2142 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -25.5%).

수익 vs 시장: 2142 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -25.5%).

고성장 수익: 2142 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: 2142 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -7.2%).

고성장 매출: 2142 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -7.2%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: 2142의 자본 수익률은 3년 후 11%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/04 05:59
종가	2025/10/03 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

HBM Holdings Limited는 10명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Bo Li	BofA Global Research
Jin Zhang	China International Capital Corporation Limited
Tony Ren	CLSA

HBM Holdings 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Hbm Holdings Limited Provides Unaudited Earnings Guidance for Six Months Ended June 30, 2025

HBM Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023

Forecast to breakeven in 2023

Consensus EPS estimates upgraded to US$0.05 loss

Consensus revenue estimates increase by 28%

Recent updates

First half 2025 earnings released: EPS: US$0.093 (vs US$0.002 in 1H 2024)

HBM Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 517.753 million.

Investor sentiment improves as stock rises 25%

HBM Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 517.753 million.

First half 2025 earnings released: EPS: US$0.093 (vs US$0.002 in 1H 2024)

New major risk - Revenue and earnings growth

Harbour BioMed Appoints Yajie Li as Chief Medical Officer

Subdued Growth No Barrier To HBM Holdings Limited (HKG:2142) With Shares Advancing 54%

HBM Holdings Limited to Report First Half, 2025 Results on Aug 27, 2025

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

Hbm Holdings Limited Provides Unaudited Earnings Guidance for Six Months Ended June 30, 2025

Harbour BioMed Announces Key Developments in Its Intellectual Property Protection Efforts

HBM Holdings Limited Announces the First-In-Human Phase 1 Clinical Study Design of MesoC2 At 2025 ASCO Meeting

What HBM Holdings Limited's (HKG:2142) 51% Share Price Gain Is Not Telling You

HBM Holdings' (HKG:2142) Shareholders Have More To Worry About Than Only Soft Earnings

New minor risk - Shareholder dilution

Full year 2024 earnings released

HBM Holdings Limited, Annual General Meeting, Jun 11, 2025

Investor sentiment improves as stock rises 17%

HBM Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 819.158724 million.

Harbour Biomed Appoints Michael D. Patten as Chief Strategy Officer

Now 30% overvalued after recent price rise

HBM Holdings Limited to Report Fiscal Year 2024 Results on Mar 31, 2025

Investor sentiment improves as stock rises 30%

HBM Holdings Limited (HKG:2142) Stock Catapults 78% Though Its Price And Business Still Lag The Industry

Investor sentiment improves as stock rises 33%

New major risk - Share price stability

Now 22% undervalued

Investor sentiment improves as stock rises 16%

Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Founder recently bought HK$1.4m worth of stock

Investor sentiment improves as stock rises 29%

New minor risk - Share price stability

HBM Holdings Limited (HKG:2142) Stock Catapults 58% Though Its Price And Business Still Lag The Industry

HBM Holdings Limited Announces Board Changes

Investor sentiment improves as stock rises 16%

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

HBM Holdings Limited Announces Submission of Investigational New Drug Application for HBM9378\SKB378 (ANTI-TSLP) for COPD to the National Medical Products Administration of China

HBM Holdings Limited Appoints Yifan Gao as Joint Company Secretary

Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump

Investor sentiment improves as stock rises 20%

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 17%

Harbour Biomed Announces the Latest Clinical Data on the First-In-Class Fully Human Anti-B7h7/Hhla2 Monoclonal Antibody Hbm1020 At the Esmo Congress 2024

First half 2024 earnings released: EPS: US$0.002 (vs US$0.004 in 1H 2023)

HBM Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Harbour BioMed to Present the Latest Progress of the First-In-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

HBM Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet

Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 17%

New minor risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

HBM Holdings Limited, Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S

HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

HBM Holdings Limited Announces Executive Changes

New major risk - Revenue and earnings growth

Forecast to breakeven in 2023

Consensus EPS estimates upgraded to US$0.05 loss

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023